Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Mentré F[au]:

Protection of the Human Gut Microbiome From Antibiotics. de Gunzburg J et al. J Infect Dis. (2018)

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Madelain V et al. Nat Commun. (2018)

Model Description Language (MDL): A Standard for Modeling and Simulation. Smith MK et al. CPT Pharmacometrics Syst Pharmacol. (2017)

Search results

Items: 1 to 50 of 256

1.

Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity.

Burdet C, Nguyen TT, Duval X, Ferreira S, Andremont A, Guedj J, Mentré F; DAV132-CL-1002 Study Group.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00820-19. doi: 10.1128/AAC.00820-19. Print 2019 Oct.

PMID:
31307985
2.

Robust designs accounting for model uncertainty in longitudinal studies with binary outcomes.

Seurat J, Nguyen TT, Mentré F.

Stat Methods Med Res. 2019 May 27:962280219850588. doi: 10.1177/0962280219850588. [Epub ahead of print]

PMID:
31131705
3.

Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count data.

Loingeville F, Nguyen TT, Riviere MK, Mentré F.

J Biopharm Stat. 2019 Apr 27:1-15. doi: 10.1080/10543406.2019.1607367. [Epub ahead of print]

PMID:
31032703
4.

Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up.

Tardivon C, Desmée S, Kerioui M, Bruno R, Wu B, Mentré F, Mercier F, Guedj J.

Clin Pharmacol Ther. 2019 Oct;106(4):810-820. doi: 10.1002/cpt.1450. Epub 2019 Jul 5.

PMID:
30985002
5.

Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.

Burdet C, Grall N, Linard M, Bridier-Nahmias A, Benhayoun M, Bourabha K, Magnan M, Clermont O, d'Humières C, Tenaillon O, Denamur E, Massias L, Tubiana S, Alavoine L, Andremont A, Mentré F, Duval X; CEREMI Group.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02244-18. doi: 10.1128/AAC.02244-18. Print 2019 Jun.

PMID:
30936104
6.

Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593-606, Sep/Oct 2018, DOI: 10.1002/pst.1873.

Krause A, Kloft C, Huisinga W, Karlsson M, Pinheiro J, Bies R, Rogers J, Mentré F, Musser BJ; ASA Special Interest Group on Statistics and Pharmacometrics/ASA Special Interest Group on Statistics and Pharmacometrics (SIG SxP).

Pharm Stat. 2019 May;18(3):278-281. doi: 10.1002/pst.1940. Epub 2019 Apr 1. No abstract available.

PMID:
30932340
7.

Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients.

Bastard JP, Couffignal C, Fellahi S, Bard JM, Mentre F, Salmon D, Katlama C, Raffi F, Leport C, Capeau J; ANRS CO, APROCO-COPILOTE Cohort study group.

Diabetes Metab. 2019 Mar 9. pii: S1262-3636(19)30055-2. doi: 10.1016/j.diabet.2019.02.008. [Epub ahead of print]

PMID:
30862472
8.

CPT: Pharmacometrics & Systems Pharmacology 2.0.

Mentré F.

CPT Pharmacometrics Syst Pharmacol. 2019 Apr;8(4):195-196. doi: 10.1002/psp4.12396. Epub 2019 Mar 6. No abstract available.

9.

Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder.

Couffignal C, Bertrand J, Sportiche S, Jarroir M, El Balkhi S, Djebrani-Oussedik N, Poupon J, Declèves X, Mentré F, Bellivier F.

Eur J Clin Pharmacol. 2019 Apr;75(4):519-528. doi: 10.1007/s00228-018-2605-3. Epub 2018 Dec 15.

PMID:
30554270
10.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y; LAMIDOL Study Group.

J Antimicrob Chemother. 2019 Mar 1;74(3):739-745. doi: 10.1093/jac/dky467.

PMID:
30476165
11.

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.

Madelain V, Baize S, Jacquot F, Reynard S, Fizet A, Barron S, Solas C, Lacarelle B, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Guedj J.

Nat Commun. 2018 Oct 1;9(1):4013. doi: 10.1038/s41467-018-06215-z.

12.

Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial.

Burdet C, Loubet P, Le Moing V, Vindrios W, Esposito-Farèse M, Linard M, Ferry T, Massias L, Tattevin P, Wolff M, Vandenesch F, Grall N, Quintin C, Mentré F, Duval X, Lescure FX; CloCeBa study group.

BMJ Open. 2018 Sep 1;8(8):e023151. doi: 10.1136/bmjopen-2018-023151.

13.

Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.

Berger J, Vigan M, Pereira B, Nguyen TT, Froissart R, Belmatoug N, Dalbiès F, Masseau A, Rose C, Serratrice C, Pers YM, Bertchansky I, Camou F, Bengherbia M, Bourgne C, Caillaud C, Pettazzoni M, Berrahal A, Stirnemann J, Mentré F, Berger MG.

Clin Pharmacokinet. 2019 Apr;58(4):469-482. doi: 10.1007/s40262-018-0708-8.

PMID:
30128966
14.

High acquisition rate of extended-spectrum β-lactamase-producing Enterobacteriaceae among French military personnel on mission abroad, without evidence of inter-individual transmission.

Maataoui N, Mayet A, Duron S, Delacour H, Mentré F, Laouenan C, Desvillechabrol D, Cokelaer T, Meynard JB, Ducher A, Andremont A, Armand-Lefèvre L, Mérens A.

Clin Microbiol Infect. 2019 May;25(5):631.e1-631.e9. doi: 10.1016/j.cmi.2018.07.030. Epub 2018 Aug 9.

PMID:
30099136
15.

Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection.

Burdet C, Sayah-Jeanne S, Nguyen TT, Hugon P, Sablier-Gallis F, Saint-Lu N, Corbel T, Ferreira S, Pulse M, Weiss W, Andremont A, Mentré F, de Gunzburg J.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00925-18. doi: 10.1128/AAC.00925-18. Print 2018 Oct.

16.

The Standard Output: A Tool-Agnostic Modeling Storage Format.

Terranova N, Smith MK, Nordgren R, Comets E, Lavielle M, Harling K, Hooker AC, Sarr C, Mentré F, Yvon F, Swat MJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):543-546. doi: 10.1002/psp4.12339. Epub 2018 Aug 12. No abstract available.

17.

Interrupter resistance to measure dose-response to salbutamol in wheezy preschool children.

Beydon N, Nguyen TT, Amsallem F, Denjean A, Fenu G, Seddon P, Mentré F, Alberti C, Lombardi E.

Pediatr Pulmonol. 2018 Sep;53(9):1252-1259. doi: 10.1002/ppul.24116. Epub 2018 Jul 3.

PMID:
29972634
18.

Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.

Hilgers RD, Bogdan M, Burman CF, Dette H, Karlsson M, König F, Male C, Mentré F, Molenberghs G, Senn S.

Orphanet J Rare Dis. 2018 May 11;13(1):77. doi: 10.1186/s13023-018-0820-8. Review.

19.

Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models.

Buatois S, Ueckert S, Frey N, Retout S, Mentré F.

AAPS J. 2018 Mar 29;20(3):56. doi: 10.1208/s12248-018-0205-x.

20.

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.

Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, Gunther S, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X.

PLoS Med. 2018 Mar 27;15(3):e1002535. doi: 10.1371/journal.pmed.1002535. eCollection 2018 Mar.

21.

PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.

Dumont C, Lestini G, Le Nagard H, Mentré F, Comets E, Nguyen TT; PFIM Group.

Comput Methods Programs Biomed. 2018 Mar;156:217-229. doi: 10.1016/j.cmpb.2018.01.008. Epub 2018 Jan 11.

PMID:
29428073
22.

Erratum for Madelain et al., "Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses".

Madelain V, Guedj J, Mentré F, Nguyen THT, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02093-17. doi: 10.1128/AAC.02093-17. Print 2018 Jan. No abstract available.

23.

Protection of the Human Gut Microbiome From Antibiotics.

de Gunzburg J, Ghozlane A, Ducher A, Le Chatelier E, Duval X, Ruppé E, Armand-Lefevre L, Sablier-Gallis F, Burdet C, Alavoine L, Chachaty E, Augustin V, Varastet M, Levenez F, Kennedy S, Pons N, Mentré F, Andremont A.

J Infect Dis. 2018 Jan 30;217(4):628-636. doi: 10.1093/infdis/jix604.

24.

Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced Clostridium difficile Colitis.

Burdet C, Sayah-Jeanne S, Nguyen TT, Miossec C, Saint-Lu N, Pulse M, Weiss W, Andremont A, Mentré F, de Gunzburg J.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00543-17. doi: 10.1128/AAC.00543-17. Print 2017 Oct.

25.

Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer.

Desmée S, Mentré F, Veyrat-Follet C, Sébastien B, Guedj J.

BMC Med Res Methodol. 2017 Jul 17;17(1):105. doi: 10.1186/s12874-017-0382-9.

26.

Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.

Nguyen THT, Nguyen TT, Mentré F.

Pharm Res. 2017 Oct;34(10):2119-2130. doi: 10.1007/s11095-017-2217-0. Epub 2017 Jun 28.

27.

Model Description Language (MDL): A Standard for Modeling and Simulation.

Smith MK, Moodie SL, Bizzotto R, Blaudez E, Borella E, Carrara L, Chan P, Chenel M, Comets E, Gieschke R, Harling K, Harnisch L, Hartung N, Hooker AC, Karlsson MO, Kaye R, Kloft C, Kokash N, Lavielle M, Lestini G, Magni P, Mari A, Mentré F, Muselle C, Nordgren R, Nyberg HB, Parra-Guillén ZP, Pasotti L, Rode-Kristensen N, Sardu ML, Smith GR, Swat MJ, Terranova N, Yngman G, Yvon F, Holford N; DDMoRe consortium.

CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):647-650. doi: 10.1002/psp4.12222. Epub 2017 Jul 12. No abstract available.

28.

Day-to-Day Dynamics of Commensal Escherichia coli in Zimbabwean Cows Evidence Temporal Fluctuations within a Host-Specific Population Structure.

Massot M, Couffignal C, Clermont O, D'Humières C, Chatel J, Plault N, Andremont A, Caron A, Mentré F, Denamur E.

Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00659-17. doi: 10.1128/AEM.00659-17. Print 2017 Jul 1.

29.

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Nguyen TH, Guedj J, Anglaret X, Laouénan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentré F; JIKI study group.

PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.

30.

Implementation of a non-human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations.

Piorkowski G, Jacquot F, Quérat G, Carbonnelle C, Pannetier D, Mentré F, Raoul H, de Lamballerie X.

Antiviral Res. 2017 Apr;140:95-105. doi: 10.1016/j.antiviral.2017.01.017. Epub 2017 Jan 26.

31.

Two levels of specialization in bacteraemic Escherichia coli strains revealed by their comparison with commensal strains.

Clermont O, Couffignal C, Blanco J, Mentré F, Picard B, Denamur E; COLIVILLE and COLIBAFI groups.

Epidemiol Infect. 2017 Apr;145(5):872-882. doi: 10.1017/S0950268816003010. Epub 2016 Dec 28.

PMID:
28029088
32.

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.

Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, John J, Karlsson MO, Mould DR, Pérez Ruixo JJ, Plan EL, Savic R, van Hasselt JG, Weber B, Zhou C, Comets E, Mentré F; Model Evaluation Group of the International Society of Pharmacometrics (ISoP) Best Practice Committee.

CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):87-109. doi: 10.1002/psp4.12161. Epub 2017 Feb 10.

33.

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.

Madelain V, Guedj J, Mentré F, Nguyen TH, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01305-16. doi: 10.1128/AAC.01305-16. Print 2017 Jan. Erratum in: Antimicrob Agents Chemother. 2017 Dec 21;62(1):.

34.

Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice.

Lestini G, Mentré F, Magni P.

AAPS J. 2016 Sep;18(5):1233-1243. doi: 10.1208/s12248-016-9924-z. Epub 2016 Jun 15.

35.

Hospitalization and ambulatory care in imported-malaria: evaluation of trends and impact on mortality. A prospective multicentric 14-year observational study.

Casalino E, Etienne A, Mentré F, Houzé S; Imported Malaria Hospitalization Study Group.

Malar J. 2016 Jun 7;15:312. doi: 10.1186/s12936-016-1364-9.

36.

An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models.

Riviere MK, Ueckert S, Mentré F.

Biostatistics. 2016 Oct;17(4):737-50. doi: 10.1093/biostatistics/kxw020. Epub 2016 May 10.

PMID:
27166250
37.

Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.

Desmée S, Mentré F, Veyrat-Follet C, Sébastien B, Guedj J.

Biometrics. 2017 Mar;73(1):305-312. doi: 10.1111/biom.12537. Epub 2016 May 5.

38.

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Apr 5;13(4):e1002009. doi: 10.1371/journal.pmed.1002009. eCollection 2016 Apr.

39.

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley Harouna, Kighoma PM, Koundouno FR, Réné Lolamou, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar. Erratum in: PLoS Med. 2016 Apr;13(4):e1002009. Dortenzio, Eric [corrected to D’Ortenzio, Eric]. PLoS Med. 2016 Jun;13(6):e1002066.

40.

Determinants of macroscopic anal cancer and precancerous lesions in 1206 HIV-infected screened patients.

Abramowitz L, Benabderrahmane D, Walker F, Yazdapanah Y, Yéni P, Rioux C, Bouscarat F, Lafferre E, Mentré F, Duval X.

Colorectal Dis. 2016 Oct;18(10):997-1004. doi: 10.1111/codi.13304.

PMID:
26896041
41.

Phylogenetic, virulence and antibiotic resistance characteristics of commensal strain populations of Escherichia coli from community subjects in the Paris area in 2010 and evolution over 30 years.

Massot M, Daubié AS, Clermont O, Jauréguy F, Couffignal C, Dahbi G, Mora A, Blanco J, Branger C, Mentré F, Eddi A, Picard B, Denamur E, The Coliville Group.

Microbiology. 2016 Apr;162(4):642-650. doi: 10.1099/mic.0.000242. Epub 2016 Jan 28.

42.

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.

Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, Mentré F.

Clin Pharmacokinet. 2016 Aug;55(8):907-23. doi: 10.1007/s40262-015-0364-1. Review.

43.

Drug assessment in the Ebola virus disease epidemic in west Africa.

Yazdanpanah Y, Horby P, van Griensven J, Mentre F, Nguyen VK, Malvy JM, Dunning J, Sissoko D, Delfraissy JF, Levy Y.

Lancet Infect Dis. 2015 Nov;15(11):1258. doi: 10.1016/S1473-3099(15)00344-8. No abstract available.

44.

The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.

Couffignal C, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, Roupret M, Phe V, Ciofu C, Tubach F, Mentre F, Cussenot O, Grandchamp B.

Urology. 2015 Dec;86(6):1185-90. doi: 10.1016/j.urology.2015.07.036. Epub 2015 Sep 11.

PMID:
26364695
45.

Ebola virus dynamics in mice treated with favipiravir.

Madelain V, Oestereich L, Graw F, Nguyen TH, de Lamballerie X, Mentré F, Günther S, Guedj J.

Antiviral Res. 2015 Nov;123:70-7. doi: 10.1016/j.antiviral.2015.08.015. Epub 2015 Sep 2.

46.

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development.

Swat MJ, Moodie S, Wimalaratne SM, Kristensen NR, Lavielle M, Mari A, Magni P, Smith MK, Bizzotto R, Pasotti L, Mezzalana E, Comets E, Sarr C, Terranova N, Blaudez E, Chan P, Chard J, Chatel K, Chenel M, Edwards D, Franklin C, Giorgino T, Glont M, Girard P, Grenon P, Harling K, Hooker AC, Kaye R, Keizer R, Kloft C, Kok JN, Kokash N, Laibe C, Laveille C, Lestini G, Mentré F, Munafo A, Nordgren R, Nyberg HB, Parra-Guillen ZP, Plan E, Ribba B, Smith G, Trocóniz IF, Yvon F, Milligan PA, Harnisch L, Karlsson M, Hermjakob H, Le Novère N.

CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):316-9. doi: 10.1002/psp4.57. Epub 2015 Jun 15.

47.

A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy.

Laouénan C, Guedj J, Peytavin G, Nguyen TT, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Marcellin P, Mentré F.

CPT Pharmacometrics Syst Pharmacol. 2015 Jan;4(1):e00008. doi: 10.1002/psp4.8. Epub 2014 Dec 30.

48.
49.
50.

Prediction of movement to surgical stimulation by the pupillary dilatation reflex amplitude evoked by a standardized noxious test.

Guglielminotti J, Grillot N, Paule M, Mentré F, Servin F, Montravers P, Longrois D.

Anesthesiology. 2015 May;122(5):985-93. doi: 10.1097/ALN.0000000000000624.

PMID:
25730338

Supplemental Content

Loading ...
Support Center